Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg starts XPS Pensions at 'buy'

(Sharecast News) - Analysts at Berenberg initiated coverage on consulting and administration firm XPS Pensions Group with a 'buy' rating and 440p target price on Wednesday, stating it was "a clear beneficiary" of an ever-evolving pensions environment and recent market volatility. Berenberg highlighted that XPS has seen organic revenue growth rates of more than 17% per annum over FY23-25 and a doubling of FY22's adjusted underlying earnings performance.

While the German bank expects adjusted earnings per share growth to moderate to 3% in FY26 due to one-off factors, it also reckons the underlying recurring growth drivers in pensions to endure this, which, alongside further expansion into the adjacent insurance market, should mean that EPS rebounds to growth rates of 7-9% per year over FY27-28.

XPS recently entered the insurance consulting fee market, expanding its total addressable market to £4bn and extending its services' lives beyond the buyout stage.

"Considering this growth recovery and XPS's very high earnings quality, the recent pullback in the shares to a FY27 P/E of 15.2x, or EV/EBITDA of 9.6x provides an attractive entry point, in our view," said Berenberg.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.